[The effect of heparin on release of histamine from basophils under the influence of MCAF/MCP-I in patients with bronchial asthma].
The clinical studies show that heparin, well known as an anticoagulant, inhibits early asthmatic response (EAR) and bronchial hyperactivity after allergen challenge in allergic patients. We have previously shown that heparin attenuates also the late phase of allergic reaction (LAR) Recently it has been shown that heparin modulates mastocyte mediator release. This could explain the beneficial role of heparin in EAR. The goal of this study was to explore the protective mechanism of heparin on LAR. Basophils are important cells in the development of LAR. We studied the effect of heparin on histamine release from basophils induced by anti-IgE and monocyte chemotactic-activating factor/monocyte chemotactic protein (MCAF/MCP-I). MCAF belongs to the chemokine family and is the most potent histamine releasing factor. Basophils were isolated from peripheral blood of 12 asthmatic patients. The cells were incubated with heparin in various concentrations: 10, 25, 50 and 100 U. Histamine was measured by spectrophotofluorometric method. We observed that incubation of basophils with heparin inhibits histamine release as shown in the table: [table: see text] Preincubation of anti-IgE or MCAF/MCP-I with heparin did not induce any changes in histamine release. The suggest that action of heparin depends on interaction with the cells but not with the agonists.
Antczak-Marczak
M
M
Kliniki Pneumonologii i Alergologii, Akademii Medycznej w Lodzi.
Kuna
P
P
D001249:Asthma / Q000188:drug therapy* / Q000378:metabolism; D001491:Basophils / Q000187:drug effects* / Q000378:metabolism; D018932:Chemokine CCL2 / Q000378:metabolism / Q000494:pharmacology; D004347:Drug Interactions; D006493:Heparin / Q000494:pharmacology* / Q000627:therapeutic use; D006636:Histamine Release / Q000187:drug effects*; D006801:Humans; D066298:In Vitro Techniques
D018932:Chemokine CCL2; D006493:Heparin
Wpływ heparyny na uwalnianie histaminy z bazofilów pod wpływem MCAF/MCP-I u chorych na astme oskrzelowa.